Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto 1919 in a partnership with Graesser's Chemical Works at Cefn Mawr, Wales. The venture produced vanillin, aspirin and its raw ingredient salicylic acid, and later rubber processing chemicals. In the 1920s, Monsanto expanded into basic industrial chemicals such as sulfuric acid and PCBs. Queeny's son Edgar Monsanto Queeny took over the company in 1928. In 1926 the company founded and incorporated a town called Monsanto in Illinois (now known as Sauget). It was formed to provide minimal regulation and low taxes for Monsanto plants at a time when local jurisdictions had most of the responsibility for environmental rules. It was